Core Viewpoint - Curis, Inc. is set to report its second quarter 2025 financial and operational results on August 5, 2025, with a conference call scheduled for the same day [1]. Company Overview - Curis, Inc. is a biotechnology company focused on developing emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor [3]. - Emavusertib is currently being evaluated in multiple clinical studies, including the TakeAim Lymphoma Phase 1/2 study for patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and the TakeAim Leukemia Phase 1/2 study for patients with relapsed/refractory acute myeloid leukemia (AML) [3]. - The drug has received Orphan Drug Designation from the U.S. FDA for the treatment of PCNSL, AML, and myelodysplastic syndrome (MDS) [3]. - Curis holds exclusive licensing rights to emavusertib through a collaboration with Aurigene established in 2015 [3]. - The company has licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma [3].

Core Viewpoint - Curis, Inc. has announced a definitive agreement for a registered direct offering and concurrent private placement, aiming to raise approximately $7.0 million to support its research and development efforts [1][2]. Group 1: Offering Details - Curis will issue 1,538,460 shares of common stock at a market price, along with unregistered pre-funded warrants and common warrants [1]. - The pre-funded warrants will allow investors to purchase an additional 1,538,461 shares at an exercise price of $0.01, while common warrants will allow for the purchase of 3,076,921 shares at an exercise price of $2.15 [1]. - The combined purchase price for one share and the associated common warrant is $2.275, and for one pre-funded warrant and the associated common warrant is $2.265 [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for research, development, working capital, and other general corporate purposes [2]. Group 3: Closing and Agents - The registered direct offering and concurrent private placement are expected to close on or about July 3, 2025, pending customary closing conditions [2]. - Laidlaw & Company (U.K.) Ltd. and Jones are acting as placement agents for the offerings [3]. Group 4: Regulatory Information - The shares are being offered under a shelf registration statement filed with the SEC, and a prospectus supplement will be available on the SEC's website [4]. - The unregistered warrants are being offered under an exemption from registration requirements, and Curis will file a resale registration statement with the SEC for the underlying shares [5]. Group 5: Company Overview - Curis is focused on developing emavusertib, an orally available IRAK4 inhibitor, currently in various clinical studies for treating relapsed/refractory cancers [7][8]. - Emavusertib has received Orphan Drug Designation from the FDA for multiple cancer treatments [8].

Core Insights - Curis, Inc. has appointed Dr. Ahmed Hamdy as Chief Medical Officer, enhancing its executive team with his extensive industry experience [2][3] - The company is making significant progress towards accelerated approval of its drug emavusertib for relapsed/refractory primary central nervous system lymphoma (PCNSL) in both the U.S. and Europe [2][8] - Curis reported a net loss of $10.6 million for Q1 2025, a slight improvement from a net loss of $11.9 million in Q1 2024, with revenues increasing to $2.4 million from $2.1 million year-over-year [7][18] Management and Strategy - Dr. Hamdy's appointment is expected to contribute positively to Curis's strategic direction, particularly in advancing emavusertib through regulatory processes [2][3] - The company is currently enrolling patients in the TakeAim Lymphoma study to support accelerated approval filings [2][8] Operational Highlights - Curis has successfully completed the first dosing cohort in the Ema-Ven-Aza triplet study for frontline acute myeloid leukemia (AML) and is now commencing the second cohort [5] - The ongoing TakeAim Lymphoma study has received Orphan Drug Designation for emavusertib in both the U.S. and Europe [8] Financial Performance - For Q1 2025, Curis reported revenues of $2.4 million, primarily from royalty revenues related to Erivedge® [7][18] - Research and development expenses decreased to $8.5 million from $9.6 million in Q1 2024, while general and administrative expenses also saw a decline [9][18] - As of March 31, 2025, Curis had cash and cash equivalents totaling $20.3 million, which is expected to support operations into Q4 2025 [11]